Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer—Cross-Sectional Study of Eligibility and Administration Rates

Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer—Cross-Sectional Study of Eligibility and Administration Rates

IntroductionThe PACIFC trial demonstrated a significant benefit of durvalumab consolidation immunotherapy (CIT) after definitive platinum-based chemoradiotherapy (P-CRT) for survival in stage III non-small cell lung cancer (NSCLC). It is unknown how many patients are eligible in clinical practice to...

Full description

Bibliographic Details
Main Authors: Tanja Eichkorn, Farastuk Bozorgmehr, Sebastian Regnery, Lisa A. Dinges, Andreas Kudak, Nina Bougatf, Dorothea Weber, Petros Christopoulos, Thomas Muley, Sonja Kobinger, Laila König, Juliane Hörner-Rieber, Sebastian Adeberg, Claus Peter Heussel, Michael Thomas, Jürgen Debus, Rami A. El Shafie
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Oncology
Subjects:
durvalumab eligibility rate
durvalumab admission rate
PACIFIC criteria
non-small cell lung cancer stage III
definitive platinum-based chemoradiotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.586449/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.586449/full

Similar Items